title: Dendritic cells-based T-cell immune response for the variable region of immunoglobulin light chain of myeloma and lymphoma cell lines.
abstract: The present work supported and extended a previous study (used VLIg gene segment type VkappaIV) and indicated that a considerable (P<0.001) and specific autologous T-cell proliferation, proliferative index (PI) ranged from 386.0 to 399.5 at 20% dendritic cells (DCs):T-cells ratio, restricted mainly (>80%) to the major histocompatibility complex (MHC) class-I molecules can be elicited in vitro against other different VLg gene segments (VkappaI, VkappaIII and Vlambda2) of myeloma and lymphoma cell lines through a retroviral transduction of human DCs generated from CD34+ progenitor cells by phorbol ester (PMA) and under serum-free conditions. This study also showed a lesser proliferation, but significant (P<0.05), restricted to MHC class-II molecules and specific for VLIg gene segments. The obtained proliferation was almost completely blocked (approximately 95%, P<0.001) by anti-CD86 monoclonal antibodies, which confirmed the critical role of the CD86 costimulatory molecules in the activation of naive T-cells. The resulting immune responses did not significantly differ (P>0.05) among the different types of VLIg gene segments, as VLIg-transduced DCs equally coexpressed the VLIg genes and CD86 costimulatory molecules. In conclusion, the present study could provide the basis of a VLIg-based immunotherapy in plasma cell and B-cell malignancies.
authors: Zoology Department, Faculty of Science, Ain Shams University, Cairo, Egypt
authors: Gamal
authors: G
authors: Ramadan
mesh_terms: D019138:Antibodies, Blocking / Q000494:pharmacology; D018952:Antigens, CD34 / Q000096:biosynthesis; D051940:B7-2 Antigen / Q000276:immunology; D002051:Burkitt Lymphoma / Q000276:immunology* / Q000473:pathology; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D006680:HLA Antigens / Q000378:metabolism; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007147:Immunoglobulin Light Chains / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D009101:Multiple Myeloma / Q000276:immunology* / Q000473:pathology; D023461:Myeloid Progenitor Cells / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D019076:Transgenes / Q000235:genetics
chemical_list: D019138:Antibodies, Blocking; D018952:Antigens, CD34; D051940:B7-2 Antigen; D006680:HLA Antigens; D007147:Immunoglobulin Light Chains; D007135:Immunoglobulin Variable Region